AstraZeneca Unveils State-of-the-Art R&D Facility in Cambridge
AstraZeneca has unveiled its new facility, The Discovery Centre, which will be used to support the company's focus on precision and specialized medicines, and to foster industry collaboration.
AstraZeneca has unveiled a new £1 billion (US$1.33 billion) facility in Cambridge, United Kingdom, that has been designed to high environmental standards and with the space to accommodate 2200 research scientists. The formal unveiling took place in the presence of His Royal Highness The Prince of Wales.
According to a Nov. 23, 2021 press release, the new facility, The Discovery Centre (DISC) includes advanced robotics, high-throughput screening, and artificial intelligence (AI)-driven technology. Additionally, it was specified that DISC will be used to support AstraZeneca’s focus on precision and specialized medicines while also fostering collaboration for the discovery and development of next generation therapeutics, such as nucleotide-based, gene-editing, and cell therapies.
“Our ambition […] is to not only unveil a building, but to also drive the next wave of scientific innovation,” said Pascal Soriot, CEO, AstraZeneca, in the company press release. “Our new Discovery Centre in Cambridge raises the bar for sustainable R&D and global collaboration across our industry. It will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth.”
Source: AstraZeneca
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
